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Abstract 
Diabetes mellitus is a chronic disease characterized by high levels of glucose in the blood, 
which leads to metabolic disorders with severe consequences. Today, there is no cure for 
diabetes. The current management for diabetes and derived medical conditions, such as 
hyperglycemia, cardiovascular diseases or diabetic foot ulcer, includes life style changes and 
hypoglycemia based therapy, which do not fully restore euglycemia or the functionality of 
damaged tissues in patients.  
This encourages scientists to work outside their boundaries to develop routes that can 
potentially tackle such metabolic disorders. In this regard, acellular and cellular approaches 
have represented an alternative for diabetics, although such treatments still face shortcomings 
related to limited effectiveness and immunogenicity. The advent of biomaterials has brought 
significant improvements for such approaches, and three-dimensional extracellular matrix 
analogous, such as hydrogels, have played a key role in this regard. Advanced hydrogels are 
being developed to monitor high blood glucose levels and release insulin, as well as serve as a 
therapeutic technology. 
Herein, the state of the art in advanced hydrogels for improving treatment of diabetes, from 
laboratory technology to commercial products approved by drug safety regulatory authorities, 
will be concisely summarized and discussed.  
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1. Introduction 
Diabetes mellitus (DM) is a disease of pandemic proportions with a burden that continues to 
increase alarmingly throughout the world. In 2015, 1.6 million people worldwide died from 
DM, making it the 6th ranked cause of death. (Organization, 2017) Diabetes is characterized 
by chronic hyperglycemia, which is caused by inherited or acquired deficiency in the 
production of insulin, as well as by the production of defective insulin.  
The gold standard for treatment of diabetics relies on diet, life style change and 
pharmacological therapy. Patients suffering from type I DM (TIDM), follow up the 
administration of insulin, which is often accompanied by further oral hypoglycemic agents and 
life style change (obesity management or physical activity). Similarly, patients suffering from 
type II DM (TIIDM) are subject to medication, usually metformin, which may be accompanied 
by further oral agents such as glucagon-like peptide-1 (GLP-1) receptor agonist. ("Standards 
of Medical Care in Diabetes-2017: Summary of Revisions," 2017) When acute glycaemia 
disorders are developed, patients can undergo islet or whole pancreas transplantation with 
relatively good prognostic. (Hering et al., 2016; Lebovitz, 2011) Although valuable, this 
therapy faces limitations related to its high cost, insufficient availability of donors or poor 
viability of the grafted tissue, which is also linked to lifelong immunotherapy. (Shapiro, 
Pokrywczynska, & Ricordi, 2017) 
Despite progress in medicine, there is still no cure for hyperglycemia and diabetes mellitus 
related conditions (DMRC), such as cardiovascular diseases (CVD), diabetic foot ulcer (DFU), 
among other. In recent years, the advent of biomaterials has broadened the possibilities to 
improve the current therapeutic strategies focused on treating diabetes. (Neves, Rodrigues, 
Reis, & Gomes, 2016) Hydrogels are a class of biomaterials that follow the building-up 
approach in which, water-soluble monomers form heriarchical structures to give rise more 
complex polymeric structures. Gels provide a highly moist three-dimensional (3D) network 
that can be exploited to encapsulate, protect and deliver a myriad of therapeutic compounds, 
including cells (Figure 1). This makes such materials an appealing toolbox to improve the 
current strategies that have shown limited success in treating diabetes. (Jabbari, Leijten, Xu, & 
Khademhosseini, 2016; Place, Evans, & Stevens, 2009) Advanced hydrogels are highly 
versatile since due to their viscoelastic properties they are easy to handle and transfer in a non-
invasive manner. Hydrogels are made from either naturally or synthetically-derived polymeric 
materials, however hybrids of both types of materials are increasingly developed. The latter 
represents a remarkable advantage in terms of hierarchical, physicochemical and spatial 
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organization, which in turns result in significant improvements related to biocompatibility, 
biological functionality and mechanical stability of hydrogels. (Jabbari et al., 2016)  
For treatment of diabetes, hydrogel based antidiabetic strategies seek for optimizing the 
detection of glucose level imbalances in the blood at the onset of diabetes as well as the release 
of insulin. For such a purposes, gels must accurately respond to changes in glucose levels, pH 
or temperature, from which in situ gelation is critical. (Dong et al., 2016; X. Li et al., 2017; X. 
Li et al., 2014).  
In another application, hydrogels exploiting an acellular approach are designed as therapeutic 
biologics to accelerate the healing of tissues. (Kasiewicz & Whitehead, 2017) In this case, 
drug/growth factors dosages, as well as the shear thinning, self-healing, and self-supporting 
features of gels are key to allow their therapeutic functions. (Buwalda, Vermonden, & Hennink, 
2017) Lastly, some hydrogels are used as 3D niches to support the culture of a myriad of mature 
cells as well as to promote the generation of insulin-producing cells from several progenitor 
cells. For this application, aspects related to cytocompatibility and mechanical stability, are 
still in laboratory evaluation stages, (Jabbari et al., 2016; Neves et al., 2016) although a few 
hydrogel-based products are currently commercially available or under clinical evaluation. In 
this review, the state of the art in advanced hydrogels for improving the treatment of 
hyperglycemia and DMRC will be concisely discussed, bringing insights on the future of these 
materials as medical products for treatment of diabetes.  
 
2. Biomaterials for treatment of diabetes 
Within the most popular class of biomaterials to address the limitations of diabetes therapy 
include glucose-responsive hydrogels, (Espona-Noguera et al., 2017) sheets, (Shimizu et al., 
2009) nanoparticles, (Gu et al., 2013; Szekalska et al., 2017) and glucose-responsive 
microneedle patches. (Seong et al., 2017; J. Yu et al., 2015) Overall, these materials have been 
developed to sense glucose, (Shao et al., 2017) deliver insulin and restore euglycemia (Gu et 
al., 2013; Seong et al., 2017; J. Yu et al., 2015). Other applications include serve as scaffolds 
for pancreatic tissue engineering applications (Lohmann et al., 2017) and more recently 
function as vehicles to encapsulate immunogenic agents to generate vaccine candidates to 
prevent the development of DM (Yoon et al., 2015). Thus, gels formulated from glycan or 
peptide derived polymers have mechanics and functionality that can be finely tuned to meet 
the needs of numerous therapeutic applications (Buwalda et al., 2017)  
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3. Glucose-responsive hydrogels to restore euglycemia 
Detecting high glucose rates at the onset of diabetes is a major challenge in the field. Therefore, 
it is important developing gels having accurate glucose sensitivity that can maintain sustained 
insulin release. Example of this is an injectable phenylboronic acid-based (PBA) hydrogel, 
which was developed to monitor high glucose rates once glucose links to deprotected amines 
of PBA, process that also triggers gelation. Thereafter rhodamine used as a colorimetric 
indicative can be released in a glucose level-responsive manner, making this gel a potential 
plataform to generate a glucose detection device in the near future (Dong et al., 2016) 
Substituting injection to deliver insulin can avoid painful experience for patients. In this regard, 
Wang et al. formulated a hydrogel-based microneedle array patch, which consists of polyvinyl 
alcohol (PVA) linked to N1-(4boronobenzyl)-N3-(4-boronophenyl)-N1, N1, N3, N3-
tetramethylpropane-1,3-diaminium (PVA-TSPBA) for the sustained release of insulin through 
the release of hydrogen peroxide derived from the oxidation of glucose. At physiological pH, 
the patch displays a fast glucose-dependent insulin release, which extends for up to 20 h. In 
addition, this patch restored euglycemia once placed on top of the dermis of diabetic mice. (J. 
Wang et al., 2018)  
 
Likewise, injection of insulin translates into a continuous uncomfortable experience for 
diabetics. Therefore, reducing administration doses could diminish such an inconvenient. To 
address this, a vesicular phospholipid gel encapsulating insulin within the hydrogel 
Pluronic®F127 demonstrated to allow safe and continuous release of insulin in vivo for up to 
7 days, without leading to inflammatory response. (X. Chen et al., 2018)  
Similarly, incorporating PBA-modified porous poly (lactic-co-glycolic acid) 
(PLGA) microparticles (MPs) (PBA-PLGA MPs) into a hydrogel containing dopamine-
conjugated hyaluronic acid (HA), it was possible to generate a microparticle hydrogel that 
dissociates under exposure to hyperglycemic solutions. After this, the hydrogel releases insulin 
and diabetic mice were able to control blood glucose levels after treatment with the hydrogel 
for up to 2 weeks, while showing minor inflammation. It was also noted that the hydrogel 
degraded progresively after 7 weeks. While this is an advantage by avoiding the need for 
surgical withdrawal, it is clear that subsequent implantations may be required, which in the 
long run might also compromise the comfort of diabetic patients. (Zhao et al., 2017)  
The well-defined amino acid composition makes self-assembled peptide hydrogels (SAPHs), 
advantageous in terms of reproducibility. Li et al., formulated amphiphilic SAPHs, capable of 
dissociate in a pH-responsive manner after glucose oxidation. This processes promotes the 
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release of insulin to regulate blood glucose levels in vivo. (X. Li et al., 2017) However, control 
of glucose levels was possible only for up to 6 days, which is shorter compared to PBA-PLGA 
MPs and far less than the duration of therapeutic effect achieved by transplanting whole islets. 
Further molecules rather than insulin are also incorporated into gel preparations. For example, 
three thermosensitive poly (ε-caprolactone-co-glycolic acid)-poly (ethylene glycol)-poly (ε-
caprolactone-co-glycolic acid) (PCGA–PEG–PCGA) copolymers were synthesized to carry 
Liraglutide (Lira), which is a derived from the human incretin glucagon like peptide-1 (GLP-
1). The injection of these formulations was able to regulate blood glucose in vivo, while 
reducing glycosylated hemoglobin after 3 administrations within 1 month. Because of the 
outcomes observed, the authors suggest this gel could constitute an option for a weekly 
treatment of TIIDM patients. (Y. Chen et al., 2016)  
 
Chitosan offers good biocompatibility and biodegradability, for this reason a deoxycholic 
modified-glycol chitosan hydrogel was designed to electrostatically immobilize and 
subsequently deliver the GLP-1 antagonist palmityl acylated exendin-4 (Ex-4). Ex-4 release 
facilitated euglycemia after nasal administration of the chitosan hydrogel into the lungs of 
diabetic mice by several weeks. (J. Lee et al., 2012) Clinical evaluation of these hydrogel 
should shed light on the actual feasibility of safely controlling glucose levels in diabetic 
patients. Furthermore, it seems reasonable to investigate prolonged application in diabetic 
volunteers. Figure 2 exemplifies some glucose-responsive hydrogel approaches currently 
avalilabe to restore euglycemia. 
 
4. Naturally-derived hydrogels for cell encapsulation. 
Today, formulating hydrogels to harbor both pancreatic and progenitor cells to restore 
euglycemia is one common strategy in the field. Alginate is an anionic polymer, which has 
been used to encapsulate human cells (L. A. Llacua, Hoek, de Haan, & de Vos, 2018) and 
functional moieties, such as collagens type IV and VI, and laminins (Table 1). (A. Llacua, de 
Haan, Smink, & de Vos, 2016) Animal pancreatic islets have been used too, despite 
immunogenicity has been linked to alginate. (de Vos, Faas, Strand, & Calafiore, 2006)  
Modifying alginate gelation parameters has facilitated the insulin secretion of murine INS1E 
cells, (Espona-Noguera et al., 2018) while human embryonic stem cells (hESCs) cultured 
inside alginate hydrogels were albe to commit into an endocrine profile after growth factor 
stimuli. In such cases, that cellular differentiation is stronger under 3D cultures in comparison 
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to 2D cultures, (Richardson, Kumta, & Banerjee, 2014) highlighting the key role of gels as 3D 
matrices to allow physiological functions of cells. 
Combining 3D matrices with bioloectronics is a current approach with promising outcomes in 
diabetes medicine. Shao and co-workers, formulated an alginate hydrogel, which along with 
poly-(L-lysine)-alginate beads formed a wireless smartphone-assisted bioelectronics-glucose 
responsive device. The production of human GLP-1 and murine insulin from genetically 
engineered cells inside the alginate hydrogel could be remotely triggered through a far-red light 
(FRL)-responsive optogenetic interface. Additionally, a custom-engineered Bluetooth-active 
glucometer, facilitated normoglycemia in vivo. (Shao et al., 2017) This elegant engineering 
approach might represent an advantageous tool to automatically control glycemic levels in 
diabetics.  
 
By means of using a synthetic nanoporous polymer that is capable of releasing Ca+2, it was 
possible to boost in situ cross-linking of alginate to form hydrogels, which encapsulated murine 
islets and once transferred into diabetic mice restored euglycemia over 3 months. In the case 
of immunodeficient mice transplanted with human islets, the therapeutic effect was prolonged 
for up to 4 months. This hydrogel could be retrieved from tissue after surgery, which suggests 
that in the event of failure, malfunction, or exhaustion of cells contained within, it could be 
possible remove it from a diabetic patient. (An et al., 2018)  
 
Another example includes the transfer of human islets within an alginate hydrogel into 
immunodeficient diabetic mice, which achieved euglycemia. Thereafter, this formulation was 
intraperitoneally transferred into a diabetic patient, where it showed to be glucose-responsive 
over 3 months. However, the grafted islets aggregated in the abdominal wall area of the patient 
after transfer, (Jacobs-Tulleneers-Thevissen et al., 2013) which encourages further 
investigations to optimize such an inssue, as well as to rule out any rejection or immunogenicity 
derived from hydrogel treatment.  
 
The production of insulin is dependent of collagens present in the pancreatic extracellular 
matrix (ECM). (Kim & Lee, 2014) This has been shown when porcine islets (McEwan et al., 
2016) and murine angiogenic cells (McBane et al., 2013) were cultured within hybrid gels 
made of collagen and chitosan, respectively. Moreover, the interaction between pancreatic cells 
and collagens is key to regulate the metabolism of the pancreas and signalling pathways 
involved in promoting cell survival. (Kim & Lee, 2014)  
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Hyaluronic acid (HA) is a non-sulphated glycosaminoglycan that regulates cell growth and 
differentiation. In a recent investigation thiolated HA and denatured collagen were cross-linked 
with polyethylene glycol diacrylate (PEGDA) to form a hydrogel capable of encapsulating 
canine islet cells and control blood glucose levels in diabetic rats. This hybrid gel was well 
tolerated at long term as opposed to unencapsulated islets. These promising results must be 
confirmed in other species, given that host response may differ and lead to reduced half-life or 
an increased degradation in other subjects. (Harrington, Williams, Rawal, Ramachandran, & 
Stehno-Bittel, 2017)  
 
Other hydrogels such as a protein-derived hydrogel (10Q6/5K80) (Beenken-Rothkopf et al., 
2013) and Matrigel®  have shown to support the differentiation and physiological functions of 
both human and murine insulin-producing cells under specific stimuli. (Greggio et al., 2013; 
Lemper et al., 2015; Takeuchi, Nakatsuji, & Suemori, 2014) However such investigations 
remain confined to laboratory assays. This is mainly true for Matrigel® due to the nature of 
source forming it.  
 
5. Synthetically-derived hydrogels for cell encapsulation. 
Synthetic hydrogels are usually highly reproducible and display little or null immunogenicity 
(Table 1). (Mehrali et al., 2017) However, sinthetic gels lack of biofunctionality, which can be 
provided through the incorporation of pancreatic ECM proteins such as, collagen type VI and 
laminin into synthetic gels to induce pancreatic physiological functions. (L. A. Llacua, Faas, 
& de Vos, 2018)  A PEG dimethacrylate (PEGDM)-based hydrogel favored the culture of 
MIN6 murine  cells, which after transferred in vivo restored euglycemia over 25 days. (Weber, 
He, Bradley, Haskins, & Anseth, 2006) In addition, the encapsulation of whole ECM proteins 
inside the same gel, improved the function of MIN6cells over 1 month. This was mainly 
observed when the highest content of laminin was used. Interestingly, such an insulin 
production was higher in comparison to PEGDM hydrogels functionalized with laminin-
derived peptides (Weber & Anseth, 2008) showing that the short peptide moieties had a limited 
effect in comparison to the whole proteins. Further investigations should be conducted to shed 
light on the mechanisms orchestrating the cellular physiological response when either short 
moieties or whole proteins are used to stimulate cells in gels.  
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Similarly, a RGD, IKVAV and GLP-1 functionalized PEG hydrogel was shown to support the 
survival of murine bone marrow-mesenchymal stem cells (BM-MSCs) and pancreatic islets, 
where insulin production was enhanced upon glucose and immobilized GLP-1 stimulation. 
(Bal et al., 2017) The immobilization of GLP-1 and IKVAV within the same hydrogel 
significantly favored the growth of RINm5F cells. Pancreatic cells inside the hydrogel also 
were capable of producing insulin, mainly upon glucose stimulation. (Lin & Anseth, 2009) 
Even such hydrogels can extend the life span of pancreatic molecules, the short cell culture 
timing assessed open the question of whether these hydrogels can remain stable under in vivo 
conditions for extended time, and without raising immunogenic reactions.  
 
In order to promote angiogenesis a PEG-maleimide hydrogel was functionalized with vascular 
endothelial growth factor (VEGF) and RGD. The hydrogel supported the growth of syngeneic 
murine islets and promoted angiogenesis in situ after different extrahepatic areas of diabetic 
mice were explored to assess islets survival. After treatment, normoglycemia could be restored 
over 1 month in vivo. (Weaver et al., 2017) This PEG hydrogel showed similar effects when 
transferred into bowel mesentery, which is lesser vascularized than the epididymal fat tissue. 
(Phelps, Headen, Taylor, Thule, & Garcia, 2013) Further investigations are necessary to 
disscard any angiogenic effect derived from the inherent vascularization of the extrahepatic 
areas explored. 
Overall hydrogels usually offer poor stability under physiological conditions. Therefore, 
blending two polymers having distinctive ductile and rigid properties facilitates the 
development of stronger hydrogels. (Gong, 2010; Ozawa, Okitsu, & Takeuchi, 2017) Alginate 
and polyacrylamide (PAAm) were combined to form a hydrogel that displayed superior 
mechanics (10-fold tensile strength) than a hydrogel formed only by alginate. The hybrid gel 
supported the production of insulin by MIN6-m9 cells and once transferred into diabetic mice, 
the hydrogel restored euglycemia and could be retrieved in a well-structured shape. (Ozawa et 
al., 2017) However, the hypoglycemic effect that this gel achieved still remains short in 
comparison to human therapeutic needs.  
In this regard, a fully synthetic hydrogel made of poly (N-isopropylacrylamide) (PIPAAm) and 
PEG, showed the ability to support the proliferation of murine islets and restored 
normoglycemia at longer time (over 4 months) than the previous alginate/PAAm gel in vivo. 
(Kodama et al., 2009)  
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6. Hydrogels for treatment of diabetes related conditions 
In the last decades there has been a surge of research in the area of biomaterials to engineering 
materials that have led to various hydrogel-based systems for the treatment of DM related 
conditions (DMRC) (Table 2). In this section it will be summarized advanced hydrogels that 
are following acellular and cellular approaches for such a purpose. 
 
6.1 Acellular naturally-derived hydrogels for cardiovascular affections 
The development of cardiovascular disease (CVD) is strongly linked to diabetes. 
Hyperglycemia increases oxidative stress, which leads to vascular complications. Coronary 
calcifications during diabetes also impairs myocardial function. (Schnell et al., 2013) One 
principal CVD is myocardial infarction (MI), whose management includes medication (anti-
inflammatory, anticoagulant and fibrinolytic agents). CVD also may lead to the need of whole 
heart or synthetic implants transplantation. (Hasan et al., 2015) The low availability of donors, 
and the limited lifespan of implants makes it necessary to look for alternatives such as the 
injection of cardiac cells and stem cells. However, this faces restrictions related to 
immunogenicity, poor cellular retention, and biological activity. (Saludas, Pascual-Gil, 
Prosper, Garbayo, & Blanco-Prieto, 2017) Today, MI is being addressed by advanced 
hydrogels (Table 2). For example, an in situ polymerizable alginate hydrogel injected into a 
swine-based myocardial infarction model, was shown to be safe, since neither vascular 
thrombi, ischemia or abnormal cardiac functions were observed. Additionally, the hydrogel 
favored the migration of myofibroblasts in the treated tissue and showed full degradation within 
2 months after transfer. (Leor et al., 2009) In a different MI model (Fisher rats) it was shown 
that both VEGF and platelet derived growth factor (PDGF) within an alginate hydrogel 
improved systolic functions and promoted angiogenesis after both were released over 4 weeks 
of treatment. (Hao et al., 2007)  
 
6.2 Cellular naturally-derived hydrogels for cardiovascular affections 
Basic research conducted to explore the viability of cardiac cells inside naturally-derived 
matrices is still ongoing (Table 2), such is the case of murine cardiac cells cultured within 
Matrigel®, which were capable of behave in a physiological-like manner, as they formed 
cardiac-like fibers. (Bakunts, Gillum, Karabekian, & Sarvazyan, 2008) Likewise, a collagen 
hydrogel showed supported the differentiation and contraction of cardiac myofibroblasts, after 
being stimulated with transforming growth factor-beta (TGF-). (Lijnen, Petrov, & Fagard, 
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2003) Similarly, a porcine decellularized heart ECM and collagen I-derived hydrogel was 
shown to support the growth of human cardiac cells, which were capable of beating without 
further stimulation. (Duan et al., 2011)  
In a different investigation, the stiffness and electrical conductivity of a collagen hydrogel were 
tuned by combining collagen with carbon nanotubes to allow the culture of cardiac cells. The 
resulting hydrogel was capable of supporting the growth and rhythmical contraction of murine 
cardiomyocytes. (H. Yu, Zhao, Huang, & Du, 2017) While such investigations clearly show 
the suitability of hydrogels to allow physiological functions of cardiac cells, future 
investigations in vivo are necessary to confirm the feasibility of using such systems under 
physiological conditions at long term.   
 
In this context, an angiopoietin-1 derived peptide QHREDGS-functionalized chitosan/collagen 
hydrogel promoted the survival of murine cardiomyocytes in vitro. After subcutaneous 
transference of the chitosan solution into the back of rats, gelation was induced in situ, which 
facilitates the retention of the hydrogel in the treated tissue and induced the growth of 
myofibroblasts and cardiomyocytes after 1 week of being transferred. (Reis et al., 2012)  
 
Biomedical devices must be handy for surgeons, which is a challenge for biomedical engineers. 
In this context, a fibrin gel has shown to allow the contraction of murine cardiomyocytes upon 
electrical stimulation under 3D cell culture conditions. (Yuan Ye, Sullivan, & Black, 2011) 
Likewise, fibrin was recently used to develop a hydrogel capable of passing throughout 
catheters for cardiac tissue engineering applications. The hydrogel also was shown to support 
the culture of human mesenchymal stem cells (hMSCs), which after following intramyocardial 
delivery in vivo, promoted the retention of hMSCs. (Martens et al., 2009)  
Inducing vascularization is a common approach to improve the functionality of myocardium 
mainly following infarction. Such is the case of another fibrin hydrogel, which supported the 
migration of murine endothelial progenitor cells in vitro. Thereafter, the hydrogel containing a 
high density of endothelial cells induced vascularization of ischemic myocardium after grafted 
in vivo. This treatment also succeeded to reduce myocardial fibrosis after 4 weeks, which 
resulted in reduction of scarring. (Atluri et al., 2014) As for other hydrogel systems, further 
investigations are yet necessary to assess the biofunctionality of fibrin gels at clinical stages. 
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6.3 Cellular synthetically-derived hydrogels for cardiovascular affections 
Within synthetic formulations allowing in situ gelation (Table 2), a PEG hydrogel 
encapsulating erythropoietin (EPO) favored the 3D culture of human induced pluripotent stem 
cells (iPSCs)-derived cardiomyocytes in vitro. The gelation of PEG solution occurred after it 
came into contact with the physiological environment and the hydrogel degradation was 
inversely proportional to the polymer concentration. The injection of the hydrogel containing 
both iPSCs and EPO into infarcted murine muscle led to the formation of cardiac tissue over 
10 weeks of treatment. (Chow et al., 2017) 
 
In addition, a Poly (N-isopropylacrylamide) (PNIPAAm) hydrogel was combined with single-
wall carbon nanotubes (SWCNTs) to improve electrical conductivity and promote cellular 
adhesion. Murine adipose-derived stem cells (ADSCs) proliferated on the surface of the 
hydrogel. Furthermore, the composite gel promoted cardiac differentiation of ADSCs when 
transferred into infarcted myocardium in vivo, where cardiac functions improved after 1 month 
of hydrogel treatment. (X. Li et al., 2014) 
The aforementioned investigations put into perspective the suitability of hydrogels for 
encapsulating cells and biomolecules to improve cardiac tissue functions. Likewise, in situ 
gelation significantly increases cell viability and retention. However, increasing the use of 
human cells when hydrogel systems are tested, could shed light on relevant physiological 
findings that can facilitate the transition of hydrogel-based technologies to the clinic.    
 
6.4 Hydrogel-based bed dressing for DFU application 
Diabetic foot ulcer is a serious medical complication associated with a high proportion of 
diabetics. It is estimated that 15% of them will develop the condition during their lifetime. 
(Reiber, Lipsky, & Gibbons, 1998) DFU can be either non-traumatic or can occur following 
accidental trauma, which commonly happens due to diabetic peripheral neuropathy. The 
condition is characterized by defective healing derived from ischemia of nerve tissue, which 
can lead to serious bacterial infections. In late stages, such an infection can turn into limb 
gangrene that often undergoes surgical amputation. The main strategies for DFU management 
include wound bed preparation, revascularization and treatment of any infection or chronic 
inflammation. Therefore, the inherent moist provided by hydrogels to balance hydration along 
with the incorporation of growth factors makes them highly appealing for DFU treatment 
(Table 2). (Jeffcoate & Harding, 2003; Sukumar, Ramachandran, Kalaiarasi, & Sengottuvelu, 
2015)  
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6.4.1 Angiogenic hydrogel-based bed dressing  
In order to induce angiogenesis, a thermosensitive and antioxidant bed dressing called H-
HKUST-1, was developed combining poly (PEG citrate) acrylate prepolymer (PPCac) and 
NIPAM (PPCN hydrogel) (Table 2). This hydrogel encapsulated copper nanoparticles (NPs) 
(H-HKUST-1 NPs), which have ability to induce angiogenesis. The release of NPs from H-
HKUST-1 was carried out slowly and at multiple dosages to avoid any non-desired toxicity 
related to NPs. The H-HKUST-1 hydrogel induced keratinocyte survival and dermal fibroblast 
migration, without having any cytotoxic effect in vitro, which according to the authors, might 
be due to the growth factors production derived from the progressive release of copper ions. 
Wounds in diabetic mice healed over 21 days of treatment with the H-HKUST-1 hydrogel and 
it was in fact, shown to be significantly less toxic than HKUST-1 NPs alone in solution. In 
addition, H-HKUST-1 and HKUST-1 NPs promoted the formation of vascular network at the 
wound site over 32 days, representing an alternative to facilitate the healing of DFU. (Xiao, 
Chen, Yi, Zhang, & Ameer, 2017) As in the case with other hydrogels, there is a need of rule 
out toxicity at long term derived from this copper ions-loaded dressing under physiological 
conditions. 
A self-assembled N-acetylglucosamine hydrogel was used to encapsulate 
polydeoxyribonucleotide (PDRN), which is a linear DNA sequence found in the human 
placenta. When human embryonic fibroblasts and vascular endothelial cells were cultured in 
the hydrogel, the expression of angiogenic and antimicrobial markers was induced in vitro. In 
addition, the re-epithelization and granulation of infected wounds in diabetic mice were 
accelerated after treatment with the hydrogel. (X. Chen et al., 2016)  
Hajimiri et al. designed a human recombinant EGF (rhEGF)-conjugated sodium 
carboxymethyl chitosan hydrogel to extend the lifespan of rhEGF. This formulation accelerated 
the closure of wounds in a murine diabetic model within 2 weeks after treatment, results 
comparable to those under treatment with the commercially available wound dressing 
Comfeel®, which lacks of rHEGF but is capable of absorbing exudate from wounds without 
adhere. (Hajimiri et al., 2016)  
Similarly, a heparin-mimetic amphiphilic peptide (PA) hydrogel effectively accelerated the 
healing of wounds in vivo. The oligopeptides PALauryl-VVAGEGDK(pbs)S-Am (GAG-PA) 
and Lauryl-VVAGK-Am (K-PA), interact with each other covalently to form a fibrillar 
hydrogel having a net negative charge capable to bind VEGF. Moreover, heparan sulphate 
proteoglycans are known to bind fibroblast growth factor 2 (FGF-2). The heparan signals 
released from the hydrogel boosted in diabetic mice vascularization, collagen deposition, the 
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expression of -SMA, and re-epithelialization after 21 days. Moreover, the hydrogel decreased 
the production of inflammatory mediators, which according to the authors was key to accelerate 
the closure of wounds after treatment. (Senturk et al., 2017) 
Zhang and co-workers designed a hydrogel formed by chitosan, heparin and poly (-glutamic 
acid) (-PGA). In order to scavenge free radicals that are highly produced during chronic 
inflammation in wounds, the enzyme superoxide dismutase was incorporated into the hydrogel. 
The positively charged residues of chitosan link the negatively charged heparin and -PGA, 
which promote angiogenesis. Murine fibroblasts proliferated on the gel and more importantly; 
the treatment of wounds in diabetic rats with the hydrogel dressing accelerated wound healing, 
which was accompanied by collagen deposition over 21 days. (Zhang et al., 2018) The 
capability of this gel to maintain mechanical stability at long term, suggests further exploration 
in considering this technology for clinical trials.  
 
Another investigation showed that the ADSCs within F127 Pluronic hydrogel differentiated 
into fibroblastic and endothelial lineages after delivered into diabetic mice dorsal lesions. The 
treatment with the hydrogel promoted the expression of VEGF and enhanced microvessel 
density. Wounds treated with the hydrogel accelerated closure, which was accompanied by the 
formation of granulated tissue, fibroblast proliferation and collagen deposition over 14 days. 
(Kaisang et al., 2017)  
Likewise, the ionic-complemmentary peptide gel RADA-16, supported the culture of murine 
primary microvascular endothelial cells, which were capable of migrating into the hydrogel. 
Thereafter, cells formed capillary-like networks and induced the production of VEGF. 
Moreover, when the hydrogel was transferred into diabetic wounds, their closure was 
accelerated through the formation of granulated tissue and the production of VEGF after 1 
week of treatment. (Cho et al., 2012) According to the authors, a non-specific interaction 
between cells and the RAD moieties might boost the production of VEGF. 
To our knowledge there is a limited number of hydrogels for treatment of DFU being assessed 
under clinical trials. Recently, an alginate gel loaded with 1 million placenta-derived 
mesenchymal stem cells (PDMSCs) induced wound healing in a female 57-year old patient 
presenting with a 20-day DFU. This approach relies on the ability of PDMSCs to produce 
VEGF, bFGF and EGF involved in wound repair. (Zeng et al., 2017) This watershed 
investigation is a call to continue testing PDMSCs in a larger population of patients having 
similar DFU stage affection. 
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6.4.2 Anti-inflammatory hydrogel-based bed dressing  
Moving into an anti-inflammatory approach (Table 2), a glycosaminoglycan (GAG)-
functionalized PEG hydrogel was designed to covalently capture inflammatory chemokines to 
accelerate the healing of wounds. This elegant approach relies on the electrostatic interactions 
between the negatively charged sulphate groups of GAGs and the positively charged residues 
of chemokines. The heparin hydrogel was shown to effectively bind the monocyte 
chemoattractant protein-1 (MCP-1) and IL-8. Subsequently, the recruitment of human 
monocytes and polymorphonuclear cells, was impaired in vitro. Moreover, the healing of 
wounds in diabetic mice significantly accelerated upon treatment with the GAG-PEG- gel over 
10 days. When the hydrogel was transferred into human wound exudates of patients suffering 
DFU, the expression of inflammatory mediators also decreased significantly with treatment.  
(Lohmann et al., 2017)  
 
The incorporation of bee venom into a PVA/chitosan hydrogel promoted the healing of chronic 
wounds in diabetic rats by inducing the production of collagen and decreasing the expression 
of IL-6 after topical transfer. The progressive release of bee venom from the gel led to the 
healing of murine wounds over 21 days of treatment. (Amin & Abdel-Raheem, 2014)  
 
Chen et al. functionalized a N-isopropylacrylamide (NIPAAm) hydrogel with RGD to culture 
murine BM-MSCs. Such cells are known to have the capability of producing growth factors 
that aid wound healing. When cultured on RGD-NIPAAm hydrogel, BM-MSCs proliferated 
and produced transforming growth factor -1 (TGF-1) and basic fibroblast growth factor 
(bFGF) over 3 days of culture. Once the hydrogel with cells was transferred into chronic 
wounds in diabetic mice, the closure of wounds was promoted through an anti-inflammatory 
mechanism, as indicated by a decrease in the population of macrophages over time. In parallel, 
keratinocytes proliferated and induced granulation in wounds after 1 month of treatment. (S. 
Chen et al., 2015) 
 
6.4.3 Antimicrobial hydrogel-based bed dressing  
A hybrid gel made of alginate and agarose has been tested to function as an antimicrobial skin 
dressing for DFU application (Table 2). This hydrogel is constituted of alginate-based porous 
sensors loaded with resin beads having a pH-responsive dye, which are embedded within an 
alginate fiber scaffold loaded with gentamicin. This hydrogel is capable of serving as a 
  
This article is protected by copyright. All rights reserved. 
colorimetric indicator of bacterial infection through detection of changes in pH values, which 
can be recorded by a smartphone interface. Alkaline and neutral pH values were recorded for 
Pseudomonas aeruginosa and Staphylococcus aureus, respectively. Latter, the gel, efficiently 
could deliver gentamicin. (Mirani et al., 2017) This approach offers a non-invasive diagnostic 
and therapeutic alternative for treatment DFU. Furthermore, this skin dressing is made up of 
FDA approved materials, which represents a significant advantage in terms of biocompatibility 
that makes it a candidate for clinical trials. 
 
6.5 Hydrogels for treatment of nephropathy 
Nephropathy represents the major cause of end stage renal disease, and it is strongly linked to 
DM. (Fineberg, Jandeleit-Dahm, & Cooper, 2013) Diabetics may also develop chronic kidney 
disease (CDK), which affects the kidney’s structure and function. (Gaitonde, Cook, & Rivera, 
2017) CDK is treated through hemodialysis, peritoneal dialysis or kidney transplantation. 
However, such therapies have several drawbacks, including risk of infection and death after 
surgery. Further, kidney grafting faces concerns related to tissue viability and immune 
rejection. (Sinnakirouchenan & Holley, 2011) 
 
6.5.1 Hydrogels for treatment of kidney injury 
Most approaches using advanced hydrogels look for restoring kidney function to mitigate acute 
kidney injury (AKI) (Table 3). For example, the injection of a murine type I collagen gel into 
an ischemia reperfusion (IR) renal tissue model in vivo, is capable of inducing the recruitment 
of renal progenitor stem cells and MSCs. According to the authors this hydrogel might induce 
the recruitment of stem cells due to the inherent inductive properties of collagen, however it is 
worth to investigate the role of surrounding cells nearby to ease the recruitment and 
differentiation of stem cells after hydrogel injection. (S. J. Lee et al., 2018) 
Moving to cell-loaded hydrogels, a thermosensitive chitosan chloride hydrogel increased the 
retention of murine ADSCs implanted in an in vivo IR model to treat AKI. Once injected, the 
hydrogel reduced the number of ROS-producing cells and renal damage. The hydrogel also 
showed good rates of degradability and biocompatibility over 14 days of treatment. Further, 
apoptosis decreased, which correlated to the improved renal function in the animals treated 
with the hydrogel. (Gao et al., 2012) 
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6.5.2 Hydrogel-based immunotherapy for treatment of nephropathy 
Recently, IL-10 and an anti-TGF-β antibody encapsulated within an in situ polymerizable HA 
hydrogel decreased inflammation and impaired the formation of fibrotic tissue, respectively in 
murine kidneys (Table 3). A reduction of macrophage infiltration and fibrotic tissue was 
observed after 25 days of treatment when IL-10 and anti-TGF-β, respectively, were 
individually administrated, with the HA hydrogel. Although when both proteins were 
encapsulated together within the same hydrogel, the animals displayed the formation of fibrotic 
tissue, which might be due to the induction of alternative TGF-β-dependent mechanisms of 
fibrosis. (Rodell, Rai, Faubel, Burdick, & Soranno, 2015) This study highlights the role of 
biomolecules as inducers to direct cellular responses when cultured within hydrogels. 
 
Soranno et al., showed that an injectable Dock and Lock (DnL) self-assembly mechanism-
based PEG hydrogel also favored the encapsulation and delivery of IL-10 when the injected 
into the kidneys of mice without inducing any immunogenic reaction. Further, it was shown a 
reduction of fibrotic tissue upon hydrogel treatment over 35 days, which is longer than 
previously reported for the HA hydrogel. According to the authors, the aforementioned effects 
may be due to quenching of the inflammatory process, which may drive the response of 
antigen-presenting cells through IL-10. (Soranno, Lu, Weber, Rai, & Burdick, 2014) 
 
Recently chitosan was functionalized with an IGF-1-derived peptide GYGSSSRRAPQT to 
form a hydrogel capable of promoting the survival and proliferation of ADSCs under 3D cell 
culture conditions. Further, upon chitosan hydrogel/ADSCs transplantation, macrophage 
recruitment and TNF-production decreased in vivo after 3 days. This subsequently favoured 
an anti-inflammatory effect, which promoted angiogenesis and reduced fibrosis after 2 weeks 
in vivo. (Feng et al., 2016)  
 
6.6 Naturally-derived hydrogels for treatment of neuropathy 
During diabetes, sensory, autonomic and motor neuropathies can be developed. Diabetics 
suffering such neuropathies undergo tight control of glucose levels, which is accompanied by 
pain reducing drugs or surgical procedures having unsatisfactory outcomes. (Pop-Busui et al., 
2017)  
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Basic research explores the use of naturally-derived hydrogels to support the culture of various 
types of cells capable of committing into nerve cells (Table 3). Such is the case of the work led 
by Valmikinathan et al., who formulated a UV photocrosslinkable chitosan hydrogel, which 
supported the viability of hMSCs. In addition, the hydrogel promoted the differentiation of 
murine primary cortical neurons and the formation of neurite extension from murine dorsal 
root ganglion (DGR) after stimulation with conditioned media. (Valmikinathan et al., 2012) 
Likewise, a chitosan/alginate composite hydrogel was suitable to support the growth of murine 
neural stem cells, as well as olfactory ensheathing cells, which are known to facilitate the 
recovery of spinal cord injury in vivo. Both types of cells proliferated upon stimulation with 
neural supplements such as B27 and bFGF after 7 days. (G. Wang, Wang, & Huang, 2017)  
 
Another approach focuses on tunning the mechanics of silk fibrin (Hopkins et al., 2013), 
chitosan and alginate gels (Wei, Zhao, Chen, Zhang, & Zhang, 2016) to match the stiffness of 
nerve tissue to allow the growth of animal nerve cells. For example, a self-healing hydrogel 
made of N-carboxymethyl chitosan linked to oxidized sodium alginate recorded ca. 80-2000 
(Pa) stiffness, which supported the growth of murine neural stem cells mainly when cultured 
under 3D conditions upon the addition of conditioned media. (Wei et al., 2016)  
 
6.7 Synthetically-derived hydrogels for treatment of neuropathy 
In an attempt to induce nerve cell migration both short peptide sequences and whole growth 
factors introduced within hydrogels are the most common strategies used in the field (Table 3). 
Recently, a RGD-functionalized -helix-based hydrogel that combined two peptide sequences: 
hSAFp1 and hSAFp2, supported the proliferation and migration of murine embryonic neural 
stem cells. Moreover, signs of neuronal commitment were evidenced by the expression of the 
microtubule-associated protein-2 (MAP2), the formation of neurite-like processes and 
electrophysiological signs. (Mehrban et al., 2015)  
 
Likewise, a functionalized peptide gel called RGD-IKVAV-RADA16 formed from the 
combination of the oligopeptides RGD-RADA16 (fibronectin moiety) and IKVAV-RADA16 
(laminin moiety), induced the growth and migration of nerve cells once the hydrogel was 
transferred within poly-L-lactic acid (PLLA)-based tubes in a nerve injury model in vivo. 
Immigrated nerve cells within the peptide gel were capable of bridging a gap through the 
formation of oriented axons over 4 weeks. (Wu et al., 2017)  
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Recently, the F127 Pluronic hydrogel, to which a heparin sulphate was coupled, has been used 
to encapsulate both bFGF and nerve growth factor (NGF) to induce the regeneration of nerve 
tissue. Investigations in vitro showed that both bFGF and NGF were progressively released 
from the Pluronic gel over 35 days. This matched well with the improvements in motor nerve 
functionality in an injured sciatic nerve model in diabetic rats, which showed significant axon 
regeneration over 30 days of treatment after a single injection of the hydrogel having both 
growth factors. (R. Li et al., 2018)  
Even though progress has been achieved using hydrogels, the current advances in the field 
seem to be yet in early stages and future investigations are needed to achieve feasible nerve 
tissue regeneration in diabetic patients at long-term. 
 
6.8 Hydrogels for treatment of retinopathy 
Diabetic retinopathy is characterized by swelling and blood leaking from blood vessels 
nourishing the retina. The subsequent ischemia impairs the integrity of retinal cells. In severe 
cases, this medical condition often leads to blindness. Medication as well as laser surgery based 
vitrectomy, are the gold standards used to face retinopathy during diabetes. However, such 
procedures are highly invasive. The transference of retinal cells to restore ocular function 
represents a promising alternative for diabetes complaint, however as for other DMRC poor 
cell viability after grafting remains as an important challenge. (Ola, Nawaz, Khan, & 
Alhomida, 2013)  
 
6.8.1 Synthetically-derived hydrogels for treatment of retinopathy 
To our knowledge a limited number of investigations based in a hydrogel strategy have focused 
on treating diabetic retinopathy (Table 3). Recently, silicon based hydrogels have been 
designed to form contact lenses capable of progressively release Epalrestat, which is a drug 
that inhibits the activity of the enzyme aldose reductase in diabetics. Aldose reductase is known 
to cause cataract and retinopathy. Silicone hydrogels were capable of maintaining a sustained 
Epalrestat release over 7 days, while the drug permeated and accumulated in situ, after bovine 
corneas were treated with hydrogels under hyperglycemic conditions. (Alvarez-Rivera, 
Concheiro, & Alvarez-Lorenzo, 2018) 
Another investigation explored the capability of an UV photopolymerizable Poly (NIPAAm-
co-Dex-lactateHEMA) hydrogel made from NIPAAm co Dextran 2-hydroxyethyl methacryl 
lactate (HEMA-lactate) to extend the delivery of Humalog® (a rapid-acting commercially 
available insulin). This approach based its feasibility on the slow hydrogel degradation derived 
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from outer diffusion of dextran chains after hydrolysis, which allows sustained Humalog® 
releasing over 5 months in vitro. Interestingly, when the ratio of NIPAAm increased, the insulin 
release became slower, suggesting that its release is dependent on diffusion and degradation 
processes of the gel. Insulin released from the hydrogel also favored the expression of cellular 
survival kinases in murine retinas over 1 month. More significant is the fact that hydrogel 
treatment decreased apoptosis of retinal cells after a single dose without altering systemic 
glucose levels. (Imai et al., 2015)  
 
6.8.2 Hybrid gels for treatment of retinopathy 
Parker and cols., functionalized HA/methylcellulose (MC) with IGF-1, wich has the ability to 
boost the survival of retinal cells (Table 3). The so-called HAMC hydrogel displayed a MC 
part that was covalently modified to link either an IGF-1-coupled weak SH3-binding peptide 
or a IGF-1-coupled strong SH3-binding peptide. From this approach two hydrogels, HAMC-
WBP and HAMC-SBP, respectively showed steady IGF-1 releasing profiles over 10 days, 
where the latter exhibited a lower cumulative IGF-1 release in comparison to HAMC-WBP in 
a hydrogel degradation-independent manner. Further, human retinal epithelium cells cultured 
within both types of gels showed high viability and displayed a typical neural morphology. 
(Parker, Mitrousis, & Shoichet, 2016) Previously, a HAMC hydrogel alone supported the 
proliferation of murine retinal stem progenitor cells and when this hydrogel was injected into 
murine sub-retinal tissue, it degraded and left distributed cells throughout the retinal tissue after 
4 weeks of treatment. (Ballios, Cooke, van der Kooy, & Shoichet, 2010) The applications of 
advanced hydrogels for treatment of DMRC, which include diminishing inflmamatory 
responses, inducing angiogenesis or promoting physiological functions of local cells to favour 
the regeneration of affected tissues are summarized in figure 3. 
 
7. Antidiabetic pharmaceutical products 
Today, there are various membrane-based products (no hydrogels) for hyperglycemia 
treatment. These antidiabetic devices include DIABECELL®, Encaptra® and Sertolin™, which 
harbor human and porcine stem cells, which once transferred allow cellular differentiation and 
insulin production in situ. This technology is currently undergoing clinical trials (phases I and 
II). (Desai & Shea, 2017) 
 
As discussed, hydrogels are vehicles used to carry pancreatic cells, hypoclycemiants and 
insulin, being thixotropic injectable bioadhesive materials that can provide a subcutaneous 
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depot of insulin. For those reasons, there has been a lot of interest in developing hydrogel-
based formulations for controlled delivery of insulin, (Chaturvedi, Ganguly, Nadagouda, & 
Aminabhavi, 2013; Huynh et al., 2008) as well as hydrogel-based cellular scaffolds for tissue 
regeneration in DFU. (Holmes, Wrobel, Maceachern, & Boles, 2013; Vyas & Vasconez, 2014) 
In the next section, hydrogels for treatment of hyperglycemia and DFU that have been approved 
by drug safety regulatory authorities and those whose approval is on course will be concisely 
discussed (Table 4).  
 
7.1 Hydrogels as pharmaceutical products for treatment of DM and DMRC 
Recent efforts for the development of hydrogel-based formulations for the controlled and 
responsive release of insulin have been highly confined to research. (Chaturvedi et al., 2013; 
Gu et al., 2013; Huynh et al., 2008) To our knowledge, there is no hydrogel based insulin 
formulations approved by drug safety regulatory authorities on the market to date. Recently, 
Ascendis Pharma has developed the pro-drugs TransCon Hydrogel Insulin, TransCon 
Hydrogel GLP-1 and a combination of the two, which were sold to Sanofi in 2010 (Table 4). 
(Ascendis Pharma. TransCon Diabetes Program. Ascendis Pharma Inc [online], 2010; Sanofi, 
http://www.sanofi.se/l/se/sv/layout. jsp?cnt=9035046E-F46C-4) These products were based on 
the TransCon technology of Ascendis Pharma, in which insulin and GLP-1 are chemically 
conjugated to branched PEG through self-cleavable linkers that autohydrolyze under 
physiological conditions giving sustained release of the active drugs. (Ascendis Pharma. 
TransCon Diabetes Program. Ascendis Pharma Inc [online], 2010; Sanofi, 
http://www.sanofi.se/l/se/sv/layout. jsp?cnt=9035046E-F46C-4) TransCon Hydrogel Insulin is 
currently under phase II clinical trials.      
 
As earlier mentioned DFU is a common DMRC that often carries severe medical consequences. 
Advances in hydrogel-based platforms have led to the development of therapeutics potentially 
capable of improving the current DFU management strategies. (Dumville, O'Meara, 
Deshpande, & Speak, 2013) Recently, two hydrogel-based cellular skin substitute products 
have been approved by FDA for the treatment of DFU, Apligraf® and Leucopatch® (Table 4). 
Apligraf® is an allogeneic bioengineered skin substitute that is composed of two layers: a lower 
dermal layer and upper epidermal sheet. The dermal layer is made up of bovine type 1 collagen 
hydrogel that acts as a 3D scaffold for human fibroblasts. (Bell, Ivarsson, & Merrill, 1979; 
Wilkins, Watson, Prosky, Meunier, & Parenteau, 1994) The collagen acts a hydrating agent 
and structural protein, which promotes healing per se and by supporting the living fibroblasts, 
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which in turn produce other ECM structural proteins, cytokines and growth factors necessary 
for wound healing. (Wilkins et al., 1994) Despite that the collagenous matrix of Apligraf® 
supports fibroblast proliferation, the low collagen concentration of the hydrogel (0.66 mg/ml) 
showed lower persistence of fibroblasts compared to more concentrated collagen hydrogels (5 
mg/ml) over 21 days, as reported by Helary et al. (Helary, Zarka, & Giraud-Guille, 2012) 
Unlike Apligraf®, Leucopatch® is an autologous skin substitute product, which is produced 
using the patient’s own venous blood. (Lundquist, Holmstrom, Clausen, Jorgensen, & 
Karlsmark, 2013; Reapplix, 2018) The production process does not include the addition of any 
reagents or excipients and leads to the formation of a triple-layered patch. The external layer is 
made of a compact polymerized fibrin hydrogel for moisture retention. The middle layer 
consists of platelets for the release of endogenous wound healing and vascularization growth 
factors. The bottom layer composed of leucocytes is directly applied onto the wound for 
protection against bacterial infection. The patch showed high cell recovery for both platelets 
and leucocytes. High cellular concentrations (ca. 3 billion) induced high levels of growth 
factors, such as PDGF-AB and VEGF, which correlated to significant antimicrobial activity by 
leucocytes as shown in the bacterial killing assays against P. aeruginosa. (Lundquist et al., 
2013; Reapplix, 2018) 
An initial clinical trial showed that Leucopatch® enhanced wound healing in DFU patients. 
(Jorgensen, Karlsmark, Vogensen, Haase, & Lundquist, 2011) This was followed by an open 
multicenter clinical study of 41 patients with hard to heal DFU treated weekly with 
Leucopatch® that showed 32% healing within 12 weeks and 54% within 20 weeks. (Londahl 
et al., 2015) Currently, a recent randomized controlled clinical trial is running in the UK, 
Denmark and Sweden on 269 patients with hard to heal DFU with the primary outcome set as 
percentage of ulcers healed within 20 weeks. (Game et al., 2017) The outcome of this crucial 
study has yet to be reported. Despite the aforementioned advantages and potential clinical 
application of Leucopatch® as a DFU treatment product, there are a number of concerns that 
might jeopardize its accessibility to the wider population of DFU patients. These are mainly 
the need for highly skilled and trained health care professionals in specialized diabetes foot 
care clinics/healthcare centers for the on-site production of the patch. Also, a particular 
Leucopatch® device, which is a centrifuge specifically designed by the supplier for the 
production of the patch, has to be available on-site for the production process.  
Regranex® hydrogel is the only acellular growth factor based hydrogel approved by the FDA 
as a therapeutic product for DFU. Regranex® is a recombinant PDGF becaplermin in sodium 
carboxymethylcellulose (NaCMC) hydrogel. The hydrogel base acts as a carrier for 
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becaplermin. Becaplermin accelerates wound healing through the chemotactic recruitment of 
neutrophils and monocytes, thus enhancing the immune response against any possible bacterial 
infection and stimulating fibroblasts proliferation and collagen type I production. (Fang & 
Galiano, 2008) A series of clinical studies have shown statistical significance in accelerated 
wound healing for experimental groups treated with becaplermin (0.01%) in NaCMC hydrogel. 
This led to the FDA approval of Regranex® hydrogel in 1997 for DFU treatment. (Smiell et al., 
1999; Steed, 2006) A recent pharmacovigilance study has revealed an increased rate of 
mortality secondary to malignancy for patients treated with 3 or more tubes of Regranex® 
hydrogel, as reported by the supplier. (Smith&Nephew, 2018) This serious limitation should 
be considered by healthcare professionals before prescribing Regranex® hydrogel for DFU 
patients, after a risk-benefit assessment has been done, and should be totally avoided for 
patients of known malignancy history.  
 
In addition to hydrogel-based dressing such as Hyalogran®, SeaSorb®, Fibracol Plus®  and 
Algivon® (detailed in Table 4), other acellular hydrogel products such as Purilon®, Intrasite®, 
Curasite®, Dermagride®, Flaminal Forte® and Saf-Gel® have been suggested for DFU 
treatment but have not yet been approved by regulatory authorities. (Donaghue et al., 1998)  
8. Conclusions and future perspectives 
Today, life expectancy is longer for the whole population, which is in part due to the significant 
progress that medicine has achieved in recent years. This, in combination with sedentary life 
styles, poor eating habits, genetics, among other factors, has promoted the development of 
metabolic syndrome that has affected people worldwide. For this reason, medicine has urged 
scientists to develop novel strategies that may improve the current therapeutics for treatment 
of diabetes and DMRC.  
There is no doubt that advanced hydrogels as platforms of biological studies, have facilitated 
the development of devices that potentially can improve the current treatments for DM. 
However, the transition towards 3D technologies capable of improving the current therapeutics 
to face DM is still ongoing. From the literature review discussed here, it is evident that most of 
the biological studies focused in diabetes still exploit animal-based models and cells, which 
undoubtedly makes the transition to clinical stages harder. Therefore, it is imperative to turn to 
biological evaluations based as much as possible on the use of human derived biologics that 
better mirror the human physiology.  
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Since biological evaluations are increasingly carried out within 3D extracellular analogous 
such as hydrogels, it is important considering held such evaluations in situ. This means 
exploiting such 3D platforms (hydrogels or tissues) at the maximum, since the current 
disruptive methods (cellular or protein extraction) used, undoubtedly increase the variability 
and misinterpretation of the findings obtained. This will shorten the pathway to develop more 
effective routes to potentially tackle DM. 
Overall, the progress that advanced hydrogels have achieved as antidiabetic technology still 
fits early technology readiness and only a few hydrogel-based devices are available as 
pharmaceutical products for diabetic patients. However, advanced hydrogel based technology 
in combination with bioelectronics, recombinant biology, bioprinting and pharmaceutical 
industry, represent a plausible route for the development of antidiabetic alternatives for patients 
suffering from diabetes. 
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Figure 1. Schematic representation of the hierarchical polymerization forming advanced 
hydrogels. Monomers form more complex structures, which interact with each other through 
physical or chemical approaches to ultimately form self-supported hydrogels. 
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Figure 2. Schematic representation of glucose-responsive hydrogels to restore euglycemia. 
Both hydrogelbased micro-patch and injectable gels deliver insulin in the long term in a 
glucose-concentration manner under specific pH conditions. Glu = Glucose, GT = Glucose 
transporter, IR = Insulin receptor. 
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Figure 3. Schematic representation of various hydrogel applications for treatment of DM and 
DMRC. A) Hydrogels act as a vehicle of a myriad of cells and bioactive molecules to foster 
insulin production within islets, B) to tackle cardiac failure, C) kidney injury, D) retinopathy 
or E) DFU once transferred. COLs = collagens, GFs = growth factors, LMs = laminins. 
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          Table 1. Hydrogels for cell encapsulation.  
Class  
Naturally- derived 
hydrogels 
Alginate hydrogels harboring whole collagen type VI and functional ECM proteins-
derived moieties, to support the 3D encapsulation of human islets. 
Alginate hydrogel with tuned gelation properties for the culture of INS1E cells 
(pancreatic cells) and insulin production in vitro. 
Alginate hydrogel for the encapsulation and endocrine differentiation of human ESCs 
under stimuli with conditioned media in vitro. 
Alginate hydrogel Ca
+2
-dependent polymerization for the encapsulation of murine and 
human islets to restore euglycemia in vivo. 
Alginate hydrogel for 3D culture of human islets to restore euglycemia in vivo and 
supporting the activity of β-cells in clinical a trial. 
Collagen/chitosan hydrogel with tunable gelation and mechanics for culture of human 
angiogenic cells and porcine islets to induce insulin production. 
HA/denatured collagen hydrogel cross-linked with PEGDA for encapsulation of canine 
islets and restoration of normoglicemia in vivo. 
Protein (Q-30/K6) hydrogel to induce the differentiation of MIN6 β cells stimulated with 
whole proteins under 3D cell culture conditions. 
Matrigel
®
 to promote the differentiation of hESCs and murine pancreatic progenitor cells 
into insulin-producing cells under specific stimuli. 
Synthetically-
derived hydrogels  
PEGDM based-hydrogel combined with ECM proteins, as well as functionalized with 
laminin-derived moieties to induce the production of insulin by murine islets and restore 
euglycemia in vivo. 
PEG hydrogel functionalized with laminin derived moieties and GLP-1 to culture murine 
BM-MSCs and islets, as well as to induce insulin production. 
Photopolymerisable PEG hydrogel functionalized with GLP-1 and IKVAV to support 
the production of insulin by RINm5F cells. 
PEG hydrogel functionalized with RGD and VEGF for the encapsulation of murine islets 
and its transference into small bowel mesentery and epididymal fat tissues of diabetic 
mice to induce vascularization and restore normoglicemia. 
PAAm DN hydrogel/alginate with stiff mechanics for the differentiation of MIN6m9 
cells and restore normoglicemia in vivo. 
PNIPAAm-PEG hydrogel for 3D culture of murine spheroidal islets to promote 
euglycemia in diabetic mice. 
Alginate/PAAm DN hydrogel to induce the differentiation of MIN6m9 cells and restore 
normoglycemia in vivo. 
PNIPAAm-PEG hydrogel to culture murine islets to promote euglycemia in diabetic 
mice. 
Summary of hydrogels to encapsulate cells.  
BM-MSCs = bone marrow-mesenchymal stem cells, DN = double network, ECM = extracellular matrix, ESC = 
embryonic stem cells, GLP-1 = glucagon-like peptide-1, aspartic acid, respectively, HA = hyaluronic acid, 
IKVAV = isoleucine, lysine, valine, alanine respectively, PAAm = polyacrylamide, PEG = polyethylene glycol, 
PEGDA = polyethylene glycol diacrylate, PEGDM = polyethylene glycol dimethacrylate, PNIPAAm = poly (N-
isopropylacrylamide), RGD = arginine, glutamine, aspartica acid respectively, VEGF = vascular endothelial 
growth factor, 3D = three-dimensional. 
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Table 2. Advanced hydrogels to address myocardial infarction and diabetic foot ulcer. 
Medical 
condition 
Class Composition and mechanism of action 
Cardiovascular 
affections 
Acellular naturally-
derived hydrogels 
In situ polymerizable alginate gel to prevent myocardial elongation and promotes myofibroblast activity in vivo.   
Alginate hydrogel for the 3D encapsulation and release of VEGF and PDGF to induce angiogenesis and improve cardiac 
functions in vivo.  
Cellular naturally-
derived hydrogels 
Matrigel® as 3D matrix for culture of murine cardiac cells capable of forming cardiac-like fibers.   
Collagen hydrogels for culture of  heart myofibroblasts capable of beating after stimulation with TGF-β.   
Porcine ECM decellularised/collagen hydrogel to promote the differentiation of contractile cardiac cells.  
Collagen hydrogel combined with carbon nanotubes to improve gel mechanics and promote rhythmical contraction of murine 
neonatal cardiomyocytes.   
Fibrin hydrogel for the culture of murine neonatal cardiomyocytes capable of contract under electrical stimuli.  
Fibrin hydrogel for the 3D culture of human mesenchymal stem cells and favoring their retention when transferred into 
myocardium in vivo.   
Fibrin hydrogel for the 3D culture of murine endothelial progenitor cells to promote vascularization and cardiac functions of 
ischemic myocardium in vivo.   
Chitosan/collagen hydrogel functionalized with angiopoietin-1 peptide to induce the growth of myofibroblasts and 
cardiomyocytes in vivo.   
Cellular 
synthetically-
derived hydrogels 
PEG hydrogel designed for in situ gelation and encapsulation of human iPSCs derived cardiomyocytes and EPO to promote 
the formation of cardiac tissue in an infarcted model in vivo.   
PNIPAAm hydrogel having carbon nanotubes for the culture of murine cardiac cells and improve their function through 
enhanced electrical conductivity in vivo.   
Diabetic foot 
ulcer 
Angiogenic 
hydrogel-based bed 
dressing 
Silk fibroin hydrogel for encapsulation of rhEGF-conjugated chitosan/alginate beads to slowly release rhEGF and promote 
wound healing of diabetic rats.  
H-HKUST-1 hydrogel to induce angiogenesis and wound healing in vivo through the release of copper ions at long term.  
PDRN hydrogel to promote the healing of diabetic wounds in vivo.  
Chitosan hydrogel for immobilization and protection of rhEGF to accelerate wound healing in vivo.  
Heparan-mimetic amphiphilic peptide hydrogel to induce wound healing in diabetic mice by promoting angiogenesis, tissue 
granulation and decreasing the expression of anti-inflammatory mediators.  
Chitosan, heparin and poly (γ-glutamic acid) hydrogel having superoxide dismutase to scavenge free radicals and favor wound 
healing in vivo.   
F127 Pluronic hydrogel for the encapsulation of murine ADSCs to induce angiogenesis and wound closure in vivo.  
RADA16 peptide hydrogel to promote the migration of murine endothelial cells in vitro and induce wound healing in vivo.  
Alginate/placenta-derived MSCs gel to induce wound healing through stimulating the production of angiogenic growth factors 
in a patient presenting 20-day DFU.    
Heparan-functionalized PEG hydrogel to scavenge inflammatory chemokines present in DFU and impairing inflammatory 
immune cells migration in vitro, in situ and in vivo.  
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Anti-inflammatory 
hydrogel-based bed 
dressing 
PVA/chitosan hydrogel harboring bee venom to promote wound healing in diabetic rats through inducing collagen deposition 
and decreasing the production of inflammatory IL-6.   
RGD-functionalized NIPAAm  hydrogel to support culture of murine BM-MSCs and promote wound healing in vivo through 
the induction of  TGF-β1 and bFGF.  
Antimicrobial 
hydrogel-based bed 
dressing 
Alginate/agarose pH responsive hydrogel as a non-invasive colorimetric indicator of infection and an antimicrobial releasing 
device in DFU in vivo.    
Summary of advanced hydrogels to address myocardial infarction and diabetic foot ulcer.  
ADSCs = adipose tissue-derived stem cells, BM-MSCs = bone marrow-mesenchymal stem cells, bFGF = basic fibroblast growth factor, DFU = diabetic foot ulcer, ECM = 
extracellular matrix, EPO = erythropoietin, IL-6 = Interleukin 6, iPSCs = induced pluripotent stem cells, MSCs = human mesenchymal stem cells, NIPAAm = N-
isopropylacrylamide, PEG = polyethylene glycol, PDGF = platelet-derived growth factor, PDRN = N-acetylglucosamine/polydeoxyribonucleotide, PNIPAAm = poly (N-
isopropylacrylamide), PVA = polyvinyl alcohol, RADA = arginine, alanine, aspartic acid, alanine, respectively, RGD = arginine, glutamine, aspartica acid respectively, VEGF 
= vascular endothelial growth factor, rhEGF = human recombinant epidermal growth factor, TGF-β1= transforming growth factor-beta 1, 3D = three-dimensional. 
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Table 3. Advanced hydrogels to address nephropathy, neuropathy and retinopathy. 
Summary of advanced hydrogels to address nephropathy, neuropathy and retinopathy. 
ADSCs = adipose tissue-derived stem cells, bFGF = basic fibroblast growth factor, DGR = dorsal root ganglion, IGF-1 = insulin-like growth factor-1, IKVAV = isoleucine, 
lysine, valine, alanine respectively, IL-10 = Interleukin 10, NGF = nerve growth factor, PEG = polyethylene glycol, PLLA = polylactic acid, PNIPAAm = poly (N-
isopropylacrylamide), RADA = arginine, alanine, aspartic acid, alanine, respectively, RGD = arginine, glutamine, aspartica acid respectively, ROS = reactive oxygen species, 
TGF-beta1= transforming growth factor-beta 1, 2D = two-dimensional, 3D = three-dimensional. 
 
 
Medical 
condition 
Class Composition and mechanism of action 
Nephropathy 
Hydrogels for  
treatment of 
kidney injury 
Collagen hydrogel to induce the recruitment and retention of renal progenitor cells in a murine ischemia reperfusion renal model 
in vivo.   
Chitosan hydrogel functionalized with a IGF-1-derived peptide to culture ADSCs, decreasing inflammation and promoting 
angiogenesis in renal tissue in vivo. 
Hydrogel-based 
immunotherapy 
HA hydrogel to immobilise and deliver IL-10 and anti-TGF-β for treatment of chronic kidney damage through decreasing 
inflammation and fibrosis in vivo. 
PEG hydrogel to deliver IL-10 for treatment of unilateral ureteral obstruction by reducing infiltration of inflammatory cells, 
apoptosis and fibrosis in vivo. 
Chitosan hydrogel for 3D culture of ADSC and improving renal functions through reducing the production of ROS in vivo. 
Neuropathy 
Naturally-
derived 
hydrogels for 
treatment of 
neuropathy 
Chitosan hydrogel to support the 3D culture of murine primary cortical neurons and the formation of neurite extensions upon growth 
factor stimulation. 
Chitosan/alginate hydrogel for 2D culture of murine neural stem cells and olfactory ensheathing cells upon stimulation with bFGF 
and B27. 
Silk fibroin hydrogel for the release of NT-3 to allow the growth of neurite extensions of chick embryo DGR under 2D cell culture 
conditions. 
Chitosan/alginate gel to favor neural differentiation of murine neural stem cells after stimulation with conditioned media under 3D 
and 2D cell culture conditions. 
Synthetically-
derived 
hydrogels for 
treatment of 
neuropathy 
hSAF peptide gel functionalized with RGD to support the differentiation of murine embryonic neural stem cells into neural cells 
under 2D cell culture conditions. 
RADA16 hydrogel functionalized with RGD and IKVAV within a PLLA conduct to repair nerve injury in vivo. 
Heparin-F127 Pluronic hydrogel for encapsulation of bFGF and NGF and improving motor nerve functionality, axon regeneration 
and remyelination in vivo. 
Retinopathy 
Synthetic and 
hybrid gels for 
treatment of 
retinopathy 
Silicone hydrogels (HEMA/MSC-MC12/APMA) to release Epalrestat into bovine corneas in situ under hyperglycemic conditions. 
Poly (NIPAAm-co-Dex-lactateHEMA) hydrogel for long-term insulin delivery and survival of retinal cells ex vivo and in vivo. 
Hyaluronan/methylcellulose hydrogel for long-term controlled release IGF-1 in vitro and 3D culture of human retinal pigment 
epithelium cells.  
Hyaluronan/methylcellulose hydrogel for 3D culture of murine retinal stem cells and their delivery into murine subretinal tissue.  
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         Table 4. Hydrogel-based products for treatment of hyperglycemia and diabetic foot ulcer. 
Medical 
condtion 
Brand name Company Class Composition and mechanism of action Authorization 
Hyperglycemia 
TransCon 
Hydrogel Insulin 
Sanofi 
Anti-diabetic 
hydrogel 
 
Insulin conjugated to branched PEG that autohydrolysis under 
physiological conditions, providing sustained release of insulin.  
Not approved 
(under trials) 
 
TransCon 
Hydrogel GLP-1 
Sanofi 
GLP-1 conjugated to branched PEG through autohydrolysis 
responsive to pH and temperature changes. 
Not approved 
(under trials) 
 
Diabetic foot 
ulcer 
Apligraf® 
Organogenesis 
Inc. 
Allogeneic 
cellular skin 
substitute 
Bilayered bioengineered skin substitute. The dermal part is a 
collagen hydrogel for human fibroblasts 3D culture.  FDA approved. 
Leucopatch® Reapplix. 
Autologous 
cellular skin 
substitute 
Three-layer patch produced from patient’s blood: polymerized 
fibrin hydrogel layer for moisture retention and platelets layer.   FDA approved. 
Regranex® Gel Smith & Nephew. 
 
Acellular 
biologics  
Recombinant (PDGF) becaplermin in sodium 
carboxymethylcellulose hydrogel.  
FDA approved. 
Intrasite® Gel Smith & Nephew. 
Carmellose polymer and propylene glycol re-hydrates necrotic 
tissue, facilitating autolytic debridement.  
Not approved 
Purilon® Gel Coloplast. 
Sodium carboxymethylcellulose and calcium alginate. Re-
hydrates necrotic tissue, facilitating autolytic debridement.  
Not approved 
Curasite® Gel 
Izun 
Pharmaceuticals. 
Botanical extract.  
Not approved 
Dermagrid MxBiodevices. 
Denatured collagen and dextran. Hydration and nanofiber 
scaffold.  
Not approved 
(under trials) 
Flaminal Forte® Flen Pharma. 
Alginate hydrogel loaded with glucose oxidase and 
lactoperoxidase. Debrides the wound, reduces excessive protease 
activity and manages moisture balance through hydration.  
Not approved 
Saf-Gel® ConvaTec Sodium alginate hydrogel. Manages moisture through hydration.  
Hyalogran® dressing 
Anika 
Therapeutics 
Acellular 
hydrogel-based 
dressing 
Dressing formed of a HA ester. Absorbs wound exudate and fuse 
into the wound allowing for necrotic tissue removal.  
SeaSorb Ag® 
dressing 
Coloplast 
Calcium alginate, carboxymethyl cellulose and an ionic silver 
complex. Manages moisture balance through hydration, 
accompanied by anti-microbial effect through the sustained 
release of silver ions in presence of wound exudate.  
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Fibracol Plus® Acelity 
90% collagen and 10% calcium alginate. Manages moisture 
balance through hydration, accompanied by enhanced 
epithelialization. 
Algivon® dressing Advancis Medical 
Calcium alginate and Manuka honey. Manages moisture balance 
through the alginate-mediated hydration, accompanied by the 
antimicrobial effect of Manuka honey.  
       Summary of hydrogel-based products for treatment of hyperglycemia and diabetic foot ulcer.  
       HA = hyaluronic acid, GLP-1 = glucagon-like peptide-1, PDGF = platelet-derived growth factor, PEG = polyethylene glycol, 3D = three-dimensional. 
 
